Literature DB >> 22554317

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.

Mathumai Kanapathipillai1, Akiko Mammoto, Tadanori Mammoto, Joo H Kang, Elisabeth Jiang, Kaustabh Ghosh, Netanel Korin, Ashley Gibbs, Robert Mannix, Donald E Ingber.   

Abstract

A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22554317     DOI： 10.1021/nl301206p

Source DB:  PubMed          Journal:  Nano Lett        ISSN： 1530-6984            Impact factor:   11.189


  31 in total

Review 1.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

2.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

3.  Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics.

Authors:  Akiko Mammoto; Tadanori Mammoto; Mathumai Kanapathipillai; Chong Wing Yung; Elisabeth Jiang; Amanda Jiang; Kristopher Lofgren; Elaine P S Gee; Donald E Ingber
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 4.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Authors:  Haifa Shen; Tong Sun; Hanh H Hoang; Jana S Burchfield; Gillian F Hamilton; Elizabeth A Mittendorf; Mauro Ferrari
Journal:  Semin Immunol       Date:  2017-09-23       Impact factor: 11.130

Review 5.  Exploring the tumor microenvironment with nanoparticles.

Authors:  Lei Miao; Leaf Huang
Journal:  Cancer Treat Res       Date:  2015

6.  Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.

Authors:  Matthew G Rubashkin; Luke Cassereau; Russell Bainer; Christopher C DuFort; Yoshihiro Yui; Guanqing Ou; Matthew J Paszek; Michael W Davidson; Yunn-Yi Chen; Valerie M Weaver
Journal:  Cancer Res       Date:  2014-09-01       Impact factor: 12.701

7.  Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.

Authors:  Ketan Patel; Ravi Doddapaneni; Nusrat Chowdhury; Cedar Ha Boakye; Gautam Behl; Mandip Singh
Journal:  Nanomedicine (Lond)       Date:  2016-05-12       Impact factor: 5.307

8.  New tools for the quantitative assessment of prodrug delivery and neurotoxicity.

Authors:  Lynn E Samuelson; Randy L Scherer; Michael N VanSaun; Kang-Hsien Fan; E Ashley Dozier; Kathy J Carter; Tatsuki Koyama; Yu Shyr; Michael Aschner; Gregg D Stanwood; Darryl J Bornhop; Lynn M Matrisian; J Oliver McIntyre
Journal:  Neurotoxicology       Date:  2015-02-27       Impact factor: 4.294

9.  Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.

Authors:  Tadanori Mammoto; Amanda Jiang; Elisabeth Jiang; Dipak Panigrahy; Mark W Kieran; Akiko Mammoto
Journal:  Am J Pathol       Date:  2013-08-05       Impact factor: 4.307

10.  Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.

Authors:  Ketan Patel; Ravi Doddapaneni; Vasanthakumar Sekar; Nusrat Chowdhury; Mandip Singh
Journal:  Mol Pharm       Date:  2016-04-26       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.